Article Text

Download PDFPDF
MET T992I mutation in a case of ependymoblastoma/embryonal tumour with multilayered rosettes
  1. Marco Gessi,
  2. Halil Demir,
  3. Tobias Goschzik,
  4. Torsten Pietsch
  1. Institute of Neuropathology, University of Bonn Medical Center, Bonn, Germany
  1. Correspondence to Dr Marco Gessi, Institute of Neuropathology, University of Bonn Medical Center, Sigmund-Freud-Strasse 25, Bonn 53127, Germany; mgessimd{at}, marco.gessi{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Ependymoblastoma/embryonal tumour with multilayered rosettes (EPBL-ETMR) represents a distinct entity among primitive neuroectodermal tumours of the central nervous system (CNS).1 ,2 They are genetically characterised by the presence of a focal 19q13.42 amplification associated with upregulation of the oncogenic miRNA cluster C19MC.1 ,2 To date, no mutations in tyrosine kinase receptor genes have been reported in these tumours. We describe a MET T992I mutation in an EPBL-ETMR affecting a 2-year-old female patient.

An MRI examination revealed a large supratentorial tumour with areas of haemorrhages and cystic features. The tumour presented at histological level with the typical EPBL-ETMR features showing highly cellular areas besides a neuropil-like matrix where several multilayered rosettes could be detected (figure 1A). As expected, the tumour was partially MAP2C (Sigma, St Louis, USA), diffuse LIN28A (Cell Signaling Technology, Danvers, USA), and focally S100-protein (Dako, Hamburg, Germany)-positive. The proliferation index, evaluated with an antibody against Ki67-Antigen (MIB-1, Dako), reached a value of 25% of stained tumour cell nuclei. Despite chemotherapy, the patient suffered …

View Full Text


  • Contributors MG, HD and TG performed experimental work. All authors have contributed to write the manuscript. All authors have revised the manuscript. All authors have seen and approved the final version of the manuscript.

  • Competing interests None.

  • Ethics approval Ethics Committee's approval for such study is not required in our institution.

  • Provenance and peer review Not commissioned; externally peer reviewed.